Literature DB >> 18977806

Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints.

D Llobet1, J Pallares, A Yeramian, M Santacana, N Eritja, A Velasco, X Dolcet, X Matias-Guiu.   

Abstract

This article reviews the main molecular alterations involved in endometrial carcinoma. Five molecular features (microsatellite instability, and mutations in the PTEN, k-RAS, PIK3CA and beta-catenin genes) are characteristic of endometrioid carcinomas, whereas non-endometrioid carcinomas show alterations of p53, loss of heterozygosity (LOH) on several chromosomes, as well as other molecular alterations (STK15, p16, E-cadherin and C-erb B2). The review also covers the phenomenon of apoptosis resistance, as well as the results obtained from cDNA array studies, and the perspectives for targeted therapies. A group of practical applications of molecular pathology techniques are also mentioned: diagnosis of hereditary non-polyposis colon cancer syndrome in patients with endometrial carcinoma; evaluation of precursor lesions; prognosis; diagnosis, particularly for synchronous endometrioid carcinomas of the uterus and the ovaries; and targeted therapies.

Entities:  

Mesh:

Year:  2008        PMID: 18977806     DOI: 10.1136/jcp.2008.056101

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  51 in total

1.  A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis.

Authors:  Núria Eritja; David Llobet; Mónica Domingo; Maria Santacana; Andree Yeramian; Xavier Matias-Guiu; Xavi Dolcet
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

2.  Histologic grade and peritoneal cytology as prognostic factors in type 1 endometrial cancer.

Authors:  Kei Tanaka; Yoichi Kobayashi; Juri Sugiyama; Tatsuo Yamazaki; Kei Dozono; Momoe Watanabe; Hiromi Shibuya; Yoshiko Nishigaya; Mai Momomura; Hironori Matsumoto; Satoshi Umezawa; Kiyoshi Takamatsu; Mitsutoshi Iwashita
Journal:  Int J Clin Oncol       Date:  2017-01-12       Impact factor: 3.402

3.  CDH1 is essential for endometrial differentiation, gland development, and adult function in the mouse uterus.

Authors:  Sarah N Reardon; Mandy L King; James A MacLean; Jordan L Mann; Francesco J DeMayo; John P Lydon; Kanako Hayashi
Journal:  Biol Reprod       Date:  2012-05-03       Impact factor: 4.285

Review 4.  Prognostic biomarkers in endometrial and ovarian carcinoma.

Authors:  Xavier Matias-Guiu; Ben Davidson
Journal:  Virchows Arch       Date:  2014-02-07       Impact factor: 4.064

Review 5.  Personalized care in uterine cancer.

Authors:  David A Iglesias; Diane C Bodurka
Journal:  Clin Adv Hematol Oncol       Date:  2012-12

6.  Knockdown of differentiation antagonizing non-protein coding RNA exerts anti-tumor effect by up-regulating miR-214 in endometrial carcinoma.

Authors:  Jingli Sun; Shaofeng Gao; Cuihua Lu
Journal:  Mol Cell Biochem       Date:  2019-06-03       Impact factor: 3.396

7.  Uterine Carcinomas in Tetrabromobisphenol A-exposed Wistar Han Rats Harbor Increased Tp53 Mutations and Mimic High-grade Type I Endometrial Carcinomas in Women.

Authors:  Janice B Harvey; Tanasa S Osborne; Hue-Hua L Hong; Sachin Bhusari; Tai-Vu Ton; Arun R Pandiri; Tiwanda Masinde; June Dunnick; Shyamal Peddada; Susan Elmore; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2015-09-08       Impact factor: 1.902

8.  Molecular profiling of endometrial malignancies.

Authors:  Norasate Samarnthai; Kevin Hall; I-Tien Yeh
Journal:  Obstet Gynecol Int       Date:  2010-03-28

9.  Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma.

Authors:  Qinglei Gao; Fei Ye; Xi Xia; Hui Xing; Yunping Lu; Jianfeng Zhou; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-02-18

10.  Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma.

Authors:  Pao-Ling Torng; Ching-Wei Lin; Michael Wy Chan; Hui-Wen Yang; Su-Cheng Huang; Chin-Tarng Lin
Journal:  Mol Cancer       Date:  2009-12-11       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.